trending Market Intelligence /marketintelligence/en/news-insights/trending/rd43kr6gmafhbe45qqljdg2 content esgSubNav
In This List

Intec Pharma to delist shares from Tel Aviv bourse

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Intec Pharma to delist shares from Tel Aviv bourse

Intec Pharma Ltd. will voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange.

The delisting will take place in three months, with the shares continuing to trade on the exchange in the interim.

The Jerusalem-based drug developer's shares will remain listed on the Nasdaq Capital Market, and will transfer shares trading in Tel Aviv to the U.S. exchange.